Arturo Md Molina Protagonist Therapeutics, Inc (PTGX) insider trading activity

Arturo Md Molina is Chief Medical Officer of Protagonist Therapeutics, Inc. Currently has a direct ownership of 106,780 shares of PTGX, which is worth approximately $9.03 Million. The most recent transaction as insider was on Jan 02, 2026, when has been sold 25,600 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 107K

27.28% 3M change

27.28% 12M change

Total Value Held $9.03 Million

ARTURO MD MOLINA Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 02 2026	BUY Grant, award, or other acquisition	-	25,600 Added 19.34%	106,780 Common Stock
Nov 17 2025	SELL Open market or private sale	$229,896 $84.77 p/Share	2,712 Reduced 3.23%	81,180 Common Stock
Jun 10 2025	SELL Open market or private sale	$570,300 $57.03 p/Share	10,000 Reduced 10.65%	83,892 Common Stock
Jun 10 2025	BUY Exercise of conversion of derivative security	$80,399 $8.04 p/Share	10,000 Added 9.63%	93,892 Common Stock
Jun 09 2025	SELL Open market or private sale	$555,100 $55.51 p/Share	10,000 Reduced 10.65%	83,892 Common Stock
Jun 09 2025	BUY Exercise of conversion of derivative security	$80,399 $8.04 p/Share	10,000 Added 9.63%	93,892 Common Stock
Mar 13 2025	SELL Open market or private sale	$1,700,850 $55.74 p/Share	30,514 Reduced 26.67%	83,892 Common Stock

Mar 13 2025	BUY Exercise of conversion of derivative security	$952,036 $31.2 p/Share	30,514 Added 21.06%	114,406 Common Stock
Jan 16 2025	SELL Open market or private sale	-	3,640 Reduced 4.16%	83,892 Common Stock
Jan 02 2025	BUY Grant, award, or other acquisition	-	41,088 Added 31.95%	87,532 Common Stock
Nov 27 2024	SELL Open market or private sale	$1,161,420 $44.67 p/Share	26,000 Reduced 35.89%	46,444 Common Stock
Nov 27 2024	BUY Exercise of conversion of derivative security	$209,039 $8.04 p/Share	26,000 Added 29.4%	62,444 Common Stock
Nov 26 2024	SELL Open market or private sale	$252,122 $45.6 p/Share	5,529 Reduced 10.64%	46,444 Common Stock
Nov 26 2024	BUY Exercise of conversion of derivative security	$44,453 $8.04 p/Share	5,529 Added 9.62%	51,973 Common Stock
Nov 15 2024	SELL Open market or private sale	$78,107 $40.98 p/Share	1,906 Reduced 3.94%	46,444 Common Stock
Jan 16 2024	SELL Payment of exercise price or tax liability	$10,517 $24.63 p/Share	427 Reduced 0.88%	48,350 Common Stock
Jan 02 2024	BUY Grant, award, or other acquisition	-	26,250 Added 34.99%	48,777 Common Stock
Nov 15 2023	SELL Open market or private sale	$30,011 $16.24 p/Share	1,848 Reduced 7.58%	22,527 Common Stock
Jan 16 2023	BUY Grant, award, or other acquisition	-	3,125 Added 11.36%	24,375 Common Stock
Nov 15 2022	BUY Grant, award, or other acquisition	-	21,250 Added 50.0%	21,250 Common Stock

Also insider at

STRO

SUTRO BIOPHARMA, INC. Healthcare

Chief Medical Officer

FMTX

Forma Therapeutics Holdings, Inc. Healthcare

Director

AMM

Arturo Md Molina

Chief Medical Officer

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PTGX shares.

Notify only if

Value

Insider Trading

Get notified when an Protagonist Therapeutics, Inc insider buys or sells PTGX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Protagonist Therapeutics, Inc

Track Activities on PTGX

Account